Data / Drug companies / Marc Glassman, Inc.
Marc Glassman, Inc.: 64 products in the FDA NDC directory, labeler code 68998
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Marc Glassman, Inc. (labeler code 68998) lists 64 products in the FDA National Drug Code Directory, covering 30 finished drugs by generic name. By type: 64 over the counter drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on August 29, 2025.
The request: Watch Marc Glassman, Inc. (FDA labeler code 68998): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68998
- Products in commercial distribution
- 64
- Packages
- 73
- Finished drugs by generic name
- 30
- Prescription products
- 0
- Over the counter products
- 64
- Flagged as original packager
- 59 of 59 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 1
- Earliest marketing start
- March 25, 2002
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 48 | 75% |
| Generic drugs (ANDA) | 16 | 25% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 64 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, coated | 28 | 43.8% |
| Tablet | 8 | 12.5% |
| Tablet, chewable | 5 | 7.8% |
| Capsule | 4 | 6.2% |
| Mouthwash | 3 | 4.7% |
| Tablet, delayed release | 3 | 4.7% |
| Shampoo | 3 | 4.7% |
| Suspension | 2 | 3.1% |
| Liquid | 2 | 3.1% |
| Capsule, liquid filled | 1 | 1.6% |
| Enema | 1 | 1.6% |
| Spray | 1 | 1.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Allergy Relief Nasal | 68998-452 | Spray, metered | Generic drugs (ANDA) | August 29, 2025 |
| 8 Hour Arthritis Pain | 68998-401 | Tablet, extended release | Generic drugs (ANDA) | October 5, 2022 |
| Pain Relief Extra Strength | 68998-392 | Tablet, coated | Over the counter monograph drugs | October 5, 2022 |
| Pain Relief Regular Strength | 68998-301 | Tablet | Over the counter monograph drugs | October 5, 2022 |
| Cold plus Head Congestion Severe | 68998-275 | Tablet, coated | Over the counter monograph drugs | October 5, 2022 |
| Cold plus Flu Severe | 68998-263 | Tablet, coated | Over the counter monograph drugs | October 5, 2022 |
| Cold Max | 68998-238 | Tablet, coated | Over the counter monograph drugs | October 5, 2022 |
| Sinus Severe | 68998-219 | Tablet, coated | Over the counter monograph drugs | October 5, 2022 |
| Pain Relief Extra Strength | 68998-198 | Tablet, coated | Over the counter monograph drugs | October 5, 2022 |
| Pain Relief PM Extra Strength | 68998-195 | Tablet, coated | Over the counter monograph drugs | October 5, 2022 |
| Pain Relief Extra Strength | 68998-104 | Tablet, coated | Over the counter monograph drugs | October 5, 2022 |
| Pain Relief PM Extra Strength | 68998-071 | Tablet, coated | Over the counter monograph drugs | September 15, 2022 |
| Pain Relief Extra Strength | 68998-070 | Tablet, coated | Over the counter monograph drugs | September 15, 2022 |
| Chewable Aspirin | 68998-205 | Tablet, chewable | Over the counter monograph drugs | August 31, 2021 |
| Allergy Relief | 68998-292 | Tablet | Generic drugs (ANDA) | July 9, 2021 |
| Stomach Relief, Ultra Strength | 68998-558 | Suspension | Over the counter monograph drugs | December 15, 2020 |
| Allergy Multi Symptom | 68998-228 | Tablet, coated | Over the counter monograph drugs | June 22, 2020 |
| Sinus Pressure plus Pain PE | 68998-220 | Tablet, coated | Over the counter monograph drugs | June 22, 2020 |
| Sinus plus Headache | 68998-323 | Tablet, coated | Over the counter monograph drugs | June 15, 2020 |
| Allergy Relief | 68998-414 | Tablet | Generic drugs (ANDA) | May 1, 2020 |
| Ibuprofen | 68998-011 | Tablet, coated | Generic drugs (ANDA) | May 1, 2020 |
| Childrens Ibuprofen Oral Suspension | 68998-320 | Suspension | Generic drugs (ANDA) | March 9, 2020 |
| Allergy Relief | 68998-194 | Tablet, coated | Generic drugs (ANDA) | March 1, 2020 |
| Ibuprofen | 68998-012 | Tablet, coated | Generic drugs (ANDA) | March 1, 2020 |
| Marcs Mucus Relief | 68998-845 | Tablet | Over the counter monograph drugs | February 26, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.